Status:
COMPLETED
The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression
Lead Sponsor:
Mclean Hospital
Collaborating Sponsors:
National Association for Research on Schizophrenia and Affective Disorders.
Conditions:
Depression
Major Depressive Disorder
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Many people with depression are treated with a serotonin-specific reuptake inhibitor anti-depressant (SSRI) and feel 'better'. Although many people feel 'better', they do not feel completely 'well'. O...
Detailed Description
As many as 65-75% of treated patients continue to experience residual symptoms of depression. Cognitive impairments feature frontal cognitive dysfunction. Many experts believe that executive functions...
Eligibility Criteria
Inclusion
- Depression
- SSRI-treated
Exclusion
- Bipolar disorder
- Serotonin-norepinephrine reuptake inhibitor (SNRI) or bupropion treatment
- Treatment-resistant depression
- Seizure disorder
- Bulimia or anorexia nervosa
- Pregnancy
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00125957
Start Date
August 1 2005
End Date
December 1 2011
Last Update
August 6 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McLean Hospital
Belmont, Massachusetts, United States, 02478